nach oben

Acta Diabetologica

Erschienen in:

01.12.2012 | Original Article

Circulating dendritic cell number and intracellular TNF-α production in women with type 2 diabetes

verfasst von: Sally E. Blank, Emily Carolyn Johnson, Debra K. Weeks, Carol H. Wysham

Erschienen in: Acta Diabetologica | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Human dendritic cell (DC) subsets perform specialized functions for surveillance against bacterial and viral infections essential for the management of type 2 diabetes (T2D). Production of tumor necrosis factor-alpha (TNF-α) by DCs acts in autocrine fashion to regulate DC maturation and promotes the inflammatory response. This study was designed to compare circulating DC number and intracellular TNF-α production between post-menopausal women with T2D and healthy women. Blood samples were obtained (n = 21/group) and examined for plasma glucose and TNF-α concentrations, and dendritic cell subset immunophenotype (plasmacytoid, pDC, CD85k(ILT-3)⁺CD123⁺CD16⁻CD14⁻ and myeloid, mDC, CD85k(ILT-3)⁺CD33⁺CD123^{dim to neg}CD16⁻CD14^{dim to neg}). Intracellular production of TNF-α was determined in unstimulated and stimulated DCs. Women with T2D had significantly (P < 0.05) greater plasma glucose and TNF-α concentrations when compared to healthy women. Women with T2D having poor glycemic control (T2D Poor Control, HbA1c ≥ 7%) had fewer circulating pDCs than women with T2D having good glycemic control (T2D Good Control, HbA1c < 7%) and healthy women. A significant interaction (P = 0.011) was observed between the effects of plasma glucose and group for intracellular expression of TNF-α in stimulated pDCs. Intracellular production of TNF-α in pDCs was significantly greater in healthy vs. T2D Poor Control (P < 0.0001) and T2D Good Control (P < 0.0001) but did not differ between T2D subgroups. The mDC number and intracellular production of TNF-α did not differ between groups. These findings indicate that TNF-α production by pDCs was reduced in women with T2D and circulating number of pDCs was associated with glycemic control.

Guest C, Park M, Johnson D, Freund G (2008) The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 13:5187–5194PubMedCrossRef

Pickup J (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823PubMedCrossRef

Pickup J, Chusney G, Thomas S, Burt D (2000) Plasma interleukin-6, tumor necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci 67:291–300PubMedCrossRef

Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K (1998) Elevated serum tumor necrosis factor-alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 41:860–862PubMedCrossRef

Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y (1998) Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83:859–862PubMedCrossRef

Bastard J-P, Maachi M, Lagathu C, Kim M, Vidal V, Caron M, Capeau J, Feve B (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4–12PubMed

Plomgaard P, Nielsen A, Fischer C, Mortensen O, Broholm C, Penkowa M, Krogh-Madsen R, Erikstrup C, Lindegaard B, Petersen A, Taudorf S, Pedersen B (2007) Associations between insulin resistance and TNF-α in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 50:2562–2571PubMedCrossRef

Catalán V, Gómez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C, Rodríguez A, Gil M, Cienfuegos J, Frühbeck G (2007) Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 17:1464–1474PubMedCrossRef

Manuel S, Rahman S, Wigdahl B, Khan Z, Jain P (2007) Dendritic cells in autoimmune diseases and neuroinflammatory disorders. Front Biosci 12:4315–4335PubMedCrossRef

10.

Banchereau J, Steinman R (1998) Dendritic cells and control of immunity. Nature 392:245–252PubMedCrossRef

11.

Soehnlein O, Weber C (2009) Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol 31:35–47PubMedCrossRef

12.

Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A, Wang K, Zou Y, Chen H (2005) Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 25:2157–2163PubMedCrossRef

13.

Seifarth C, Hinkmann D, Hahn E-G, Lohmann T, Harsch I (2008) Reduced frequency of peripheral dendritic cells in type 2 diabetes. Exp Clin Endocrinol Diabetes 116:162–166PubMedCrossRef

14.

Corrales J, Almeida M, Burgo R, Hernandez P, Miralles J, Orfao A (2007) Decreased production of inflammatory cytokines by circulating monocytes and dendritic cells in type 2 diabetic men with atherosclerotic complications. J Diabetes Complications 21:41–49PubMedCrossRef

15.

Summers K, Marleau A, Mahon J, McManus R, Hramiak I, Singh B (2006) Reduced IFN-α secretion by blood dendritic cells in human diabetes. Clin Immunol 121:81–89PubMedCrossRef

16.

Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067–2072PubMedCrossRef

17.

Ju X-S, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford G, Zenke M (2004) Immunoglobulin-like transcripts ILT2, ILT3, and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene 331:159–164PubMedCrossRef

18.

Kohrgruber N, Halanek N, Groger M, Winter D, Rappersberger K, Schmitt-Egenolf M, Stingl G, Maurer D (1999) Survival, maturation, and function of CD11c− and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. J Immunol 163:3250–3259PubMed

19.

Paharkova-Vatchkova V, Maldonado R, Kovats S (2004) Estrogen preferentially promotes the differentiation of CD11c+CD11b^intermediate dendritic cells from bone marrow precursors. J Immunol 172:1426–1436PubMed

20.

Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone B, Socci C, Di Carlo V (1999) Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 162:6473–6481PubMed

21.

Ma D, Clark E (2009) The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 21:265–272PubMedCrossRef

22.

Serbina N, Salazar-Mather T, Biron C, Kuziel W, Pamer E (2003) TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19:59–70PubMedCrossRef

23.

Matzinger P (1994) Tolerance, danger, and the extended family. Ann Rev Immunol 12:991–1045CrossRef

24.

Varo N, Libby P, Nuzzo R, Italiano J, Doria A, Schönbeck U (2005) Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2:81–87PubMedCrossRef

25.

Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual A, Bernal M, Fernádez-Cruz A, Veves A, Jarolim P, Varo J, Goldfine A, Horton E, Schönbeck U (2003) Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. A novel target of thiazolidinediones. Circulation 107:2664–2669PubMedCrossRef

26.

Blüml S, Kirchberger S, Bochkov V, Krönke G, Stuhlmeier K, Majdic O, Zlabinger G, Knapp W, Binder B, Stöckl J, Leitinger N (2005) Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 175:501–508PubMed

27.

Trevejo J, Marino M, Philpott N, Josien R, Richards E, Elkon K, Falck-Pedersen E (2001) TNF-α−dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci USA 98:12162–12167PubMedCrossRef

28.

Blanco P, Palucka A, Pascual V, Banchereau J (2008) Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19:41–52PubMedCrossRef

29.

Palucka A, Blanck J-P, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci USA 102:3372–3377PubMedCrossRef

30.

Buse J, Bigger J, Byington R, Cooper L, Cushman W, Friedewald W, Genuth S, Gerstein H, Ginsberg H, Goff D, Grimm R, Margolis K, Probstfield J, Simons-Morton D, Sullivan M (2007) Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 99:S21–S33CrossRef

31.

Ida J, Shrestha N, Desai S, Pahwa S, Hanekom W, Haslett P (2006) A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J Immunol Methods 310:86–99PubMedCrossRef

32.

Sato K, Fujita S (2007) Dendritic cells: nature and classification. Allergol Int 56:183–191PubMedCrossRef

33.

Della Bella S, Giannelli S, Taddeo A, Presicce P, Villa M (2008) Application of six-color flow cytometry for the assessment of dendritic cell responses in whole blood assays. J Immunol Methods 339:153–164PubMedCrossRef

34.

Wang J-CE, Kobie J, Zhang L, Cochran M, Mosmann T, Ritchlin C, Quataert S (2009) An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. J Immunol Methods 341:106–116PubMedCrossRef

35.

American Diabetes Association (2007) Standards of medical care in diabetes. Diabetes Care S4–S41

36.

The action to control cardiovascular risk in diabetes study group, Gerstein H, Miller M, Byington R, Goff D, Bigger J, Buse J, Cushman W, Genuth S, Ismail-Beigi F, Grimm R, Probstfield J, Simons-Morton D, Friedewald W (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef

37.

Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, Colonna M (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185:1743–1751PubMedCrossRef

38.

Vlad G, Chang C-C, Colovai A, Berloco P, Cortesini R, Suciu-Foca N (2009) Immunoglobulin-like transcript 3: a crucial regulator of dendritic cell function. Hum Immunol 70:340–344PubMedCrossRef

39.

Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M, Tabellini G, Moretta A, Sozzani S (2007) The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 109:3625–3632PubMedCrossRef

40.

Vermi W, Riboldi E, Wittamer V, Gentili F, Luini W, Marrelli S, Vecchi A, Franssen J-D, Communi D, Massardi L, Sironi M, Mantovani A, Parmentier M, Facchetti F, Sozzani S (2005) Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 201:509–515PubMedCrossRef

41.

Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer M, Schäffler A, Aslanidis C, Schölmerich J, Buechler C (2010) Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol 72:342–348CrossRef

42.

Weis M, Schlichting C, Engleman E, Cooke J (2002) Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases. Arterioscler Thromb Vasc Biol 22:1817–1823PubMedCrossRef

43.

Kadowaki N, Ho S, Antonenko S, Malefyt R, Kastelein R, Bazan F, Liu Y (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194:863–869PubMedCrossRef

44.

Kadowaki N, Antonenko S, Lau JY-N, Liu Y-J (2000) Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 192:219–226PubMedCrossRef

45.

Jing Y, Shaheen E, Drake R, Chen N, Gravenstein S, Deng Y (2009) Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol 70:777–784PubMedCrossRef

46.

Kalofoutis C, Piperi C, Zisaki A, Singh J, Harris F, Phoenix D, Alaveras A, Kalofoutis A (2006) Differences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different age. Ann N Y Acad Sci 1084:166–177PubMedCrossRef

47.

Paolisso G, Rizzo M, Mazziotti G, Tagliamonte M, Gambardella A, Rotondi M, Carella C, Giugliano D, Varricchio M, D’Onofrio F (1998) Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 275:E294–E299

48.

Katsuki A, Sumida Y, Murata K, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Gabazza E, Adachi Y (2000) Troglitazone reduces plasma levels of tumor necrosis factor-α; in obese patients with type 2 diabetes. Diabetes Obes Metab 2:189–191PubMedCrossRef

49.

Buckland M, Jago D, Fazekesova H, Scott K, Tan P, George A, Lechler R, Lombardi G (2006) Aspirin-treated human DCs up-regulate ILT-3 and induce hypo responsiveness and regulatory activity in responder T cells. Am J Transplant 6:2046–2059PubMedCrossRef

50.

Ho L-J, Chang D-M, Shiau H-Y, Chen C-H, Hsieh T-Y, Hsu Y-L, Wong C-S, Lai J-H (2001) Aspirin differentially regulates endotoxin-induced IL-12 and TNFα production in human dendritic cells. Scand J Rheumatol 30:346–352PubMedCrossRef

51.

Gosset P, Charbonnier A-S, Delerive P, Fontaine J, Staels B, Pestel J, Tonnel A-B, Trottein F (2001) Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 31:2857–2865PubMedCrossRef

52.

Soumelis V, Liu Y-J (2006) From plasmacytoid to dendritic cell: Morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol 36:2286–2292PubMedCrossRef

Titel: Circulating dendritic cell number and intracellular TNF-α production in women with type 2 diabetes
verfasst von: Sally E. Blank
Emily Carolyn Johnson
Debra K. Weeks
Carol H. Wysham
Publikationsdatum: 01.12.2012
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe Sonderheft 1/2012
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-010-0190-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2012

Human pericyte–endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment

31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients

Gender-specific effect of physical training on AQP7 protein expression in human adipose tissue

The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM)

Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells